Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) (NCT06958211)

🧪 Interventions in This Study

• Ruxolitinib Cream (DRUG)
• Vehicle Cream (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (107 Sites)

Showing the first 25 of 107 sites.

• Investigative Site US257 — Birmingham, Alabama
• Investigative Site US218 — Birmingham, Alabama
• Investigative Site US239 — Montgomery, Alabama
• Investigative Site US215 — Phoenix, Arizona
• Investigative Site US261 — Phoenix, Arizona
• Investigative Site US240 — Tucson, Arizona
• Investigative Site US262 — Encino, California
• Investigative Site US222 — Fountain Valley, California
• Investigative Site US211 — Los Angeles, California
• Investigative Site US237 — Los Angeles, California
• Investigative Site US234 — Northridge, California
• Investigative Site US250 — Santa Ana, California
• Investigative Site US244 — Castle Rock, Colorado
• Investigative Site US252 — Cromwell, Connecticut
• Investigative Site US208 — Boca Raton, Florida
• Investigative Site US203 — Hialeah, Florida
• Investigative Site US258 — Jacksonville, Florida
• Investigative Site US206 — Maitland, Florida
• Investigative Site US223 — Miami, Florida
• Investigative Site US241 — Miami, Florida
• Investigative Site US202 — Miami, Florida
• Investigative Site US214 — Tampa, Florida
• Investigative Site US247 — Tampa, Florida
• Investigative Site US231 — Columbus, Georgia
• Investigative Site US225 — Sandy Springs, Georgia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hidradenitis Suppurativa

• A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy — Phoenix, Arizona
• Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) — Phoenix, Arizona
• Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa — Boston, Massachusetts
• A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa — Phoenix, Arizona
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Birmingham, Alabama

Explore by condition: All Hidradenitis Suppurativa clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.